|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 88.89 | 103.80 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1519.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | UnAudited | Net Sales | 43,813.30 | 46,647.20 | 43,181.90 | 38,937.40 | Total Expenditure | 30,254.70 | 32,856.00 | 31,135.00 | 30,939.60 | PBIDT (Excl OI) | 13,558.60 | 13,791.20 | 12,046.90 | 7,997.80 | Other Income | 1,689.80 | 2,050.90 | 1,579.80 | 1,197.10 | Operating Profit | 15,248.40 | 15,842.10 | 13,626.70 | 9,194.90 | Interest | 90.60 | 78.00 | 3.10 | 104.60 | Exceptional Items | 0 | 0 | 0 | -1,859.00 | PBDT | 15,157.80 | 15,764.10 | 13,623.60 | 7,231.30 | Depreciation | 1,350.20 | 1,798.10 | 1,359.50 | 1,615.80 | Profit Before Tax | 13,807.60 | 13,966.00 | 12,264.10 | 5,615.50 | Tax | 3,630.00 | 3,669.10 | 3,313.90 | 2,060.60 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 10,177.60 | 10,296.90 | 8,950.20 | 3,554.90 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 11,141.40 | 10,296.90 | 8,950.20 | 3,554.90 | Equity Capital | 1,614.70 | 1,614.70 | 1,614.50 | 1,614.30 | Face Value (IN RS) | 2 | 2 | 2 | 2 | Reserves | | | | | Calculated EPS | 12.61 | 12.75 | 11.09 | 4.40 | Calculated EPS (Annualised) | 50.42 | 51.02 | 44.35 | 17.62 | No of Public Share Holdings | 536,019,518.00 | 535,994,549.00 | 535,961,284.00 | 534,110,491.00 | % of Public Share Holdings | 66.53 | 66.53 | 66.53 | 66.45 | | | | | | PBIDTM% (Excl OI) | 30.95 | 29.56 | 27.90 | 20.54 | PBIDTM% | 34.80 | 33.96 | 31.56 | 23.61 | PBDTM% | 34.60 | 33.79 | 31.55 | 18.57 | PBTM% | 31.51 | 29.94 | 28.40 | 14.42 | PATM% | 23.23 | 22.07 | 20.73 | 9.13 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|